

Oregon Board of Naturopathic Examiners - Formulary Council Meeting Minutes
October 10, 2007
Amended March 17, 2008

PRESENT: Kevin Wilson, ND (Chair); Dohn Kruschwitz, MD; Ann Blair, PhD; John Block, PhD; Rick Marinelli, ND, Anne Walsh and guests.

EXCUSED: Mike Mockler, RPh; Cathy Rakers, RPh

The meeting opened at 9:00am.

APPROVAL OF MINUTES: Minutes were approved from the March 21, 2007 meeting. All substances approved and submitted to the Board were adopted in rule at the June 2007 meeting.

COUNCIL DISCUSSION: There was discussion on having more Formulary Council Meetings with possible phone meetings when needed. Dr Marinelli suggested having extra meeting based on submissions and to encourage doctors to make submissions year around rather than waiting until the deadline. It was decided to keep meeting dates quarterly for the time being.

Drug Review (the following substances were submitted, discussed and reviewed by the FC):

<i>Item / Requestor</i>	<i>Decision</i>	<i>Category</i>
Piperazine Citrate Classification – Sedative/Hypnotic	Approved: by unanimous vote> goes to Board (RM moved; DK seconded; all in favor)	Piperazine Citrate
Eszopiclone Classification – Anti-helminic	Approved: by unanimous vote> goes to Board (RM moved; DK seconded; all in favor)	Psychotherapeutic
Ranolazine	Approved: by unanimous vote> goes to Board (RM moved; DK seconded; all in favor)	Piperazine Citrate
Sildenafil Citrate	Approved: by unanimous vote> goes to Board (RM moved; DK seconded; all in favor)	Piperazine Citrate
Trimetazidine	Approved: by unanimous vote> goes to Board (RM moved; DK seconded; all in favor)	Piperazine Citrate

Valproic Acid	Approved: by unanimous vote> goes to Board (DK moved; RM seconded; all in favor)	Anticonvulsants
Vardenafil HCL	Approved: by unanimous vote> goes to Board (RM moved; DK seconded; all in favor)	Piperazine Citrate

REVIEW BUSINESS: A motion was made by Dr. Marinelli to have Piperazine as an all inclusive category including the ED drugs, Eszopiclone, and anti- anginals in their own new category with Ranolazine, Trimetazidine. The motion was seconded by Dr. Kruschwitz and approved by all. Dr. Kruschwitz made the motion to approve Valproic Acid. The motion was seconded by Dr. Marinelli and approved by all. Dr. Marinelli made a motion to make biological an all inclusive category. The motion was seconded by Dr. Kruschwitz. The motion failed to pass with a unanimous vote. Dr. Marinelli made a motion to have under Biologicals the inclusion of Monoclonal antibodies as an all inclusive category. The motion was seconded by Dr. Krushwitz and approved by all.

NEXT MEETING DATE: The next Formulary Council meeting was set for March 19, 2008, 9:00am.

As there was no further business to discuss the meeting was adjourned at 10.39am

Trazodone (per AB 11/21/07 trazodone is not an anti-anginal or a piperazine).